Skip to main content
Clinical Trials/ACTRN12615000671561
ACTRN12615000671561
Completed
未知

Does the physical activity and sitting time reduction program enhance the cognitive benefits of physical activity in community dwelling middle-aged and older adults with type 2 diabetes: a feasibility pilot study

Academic Unit for Psychiatry of Old Age, University of Melbourne0 sites15 target enrollmentJune 29, 2015

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Academic Unit for Psychiatry of Old Age, University of Melbourne
Enrollment
15
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
June 29, 2015
End Date
December 14, 2016
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Academic Unit for Psychiatry of Old Age, University of Melbourne

Eligibility Criteria

Inclusion Criteria

  • 1\) aged between 50\-85 years; 2\) community dwelling; 3\) no known diagnosis of dementia; 4\) insufficiently active”, defined as doing less than 60 minutes/week of Moderate Vigorous Physical Activity for at least the previous 3 months; 5\) self\-reported estimated sitting time greater than/equal to 5 hrs 40 mins per day (median cut\-point from the AusDiab data set); 6\) diagnosed with Type II diabetes.

Exclusion Criteria

  • 1\) presence of medical condition that prohibits standing; 2\) unstable or life threatening medical condition; 3\) medical condition that contra\-indicates moderate physical activity; 4\) diabetes treatment with insulin; 5\) Body Mass Index (BMI) \> 40; 6\) severe visual or hearing impairment; 7\) history of chronic alcohol abuse within the past 5 years; 8\) unable to attend the visits; 9\) unable to understand spoken or written English; 10\) HbA1c level \> 8\.5 11\) unable to undergo Magnetic Resonance Imaging, 12\) Geriatric Depression Scale score greater than 6 indicating the presence of clinically significant depressive symptoms, 13\) Mini Mental State Exam score less than 24 indicating clinically significant cognitive impairment.

Outcomes

Primary Outcomes

Not specified

Similar Trials